(-)-BPAP

ID: bpap

Aliases: benzofuranylpropylaminopentane, (-)-1-(benzofuran-2-yl)-2-propylaminopentane

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: mechanistic, preclinical

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• TAAR1 agonist or modulator
• catecholaminergic activity enhancer

Optimization domains

• motivation
• dopamine
• CNS

Research basis

• TAAR1/dopaminergic release modulation is mechanistically interesting.
• Low-dose enhancer claims make it a frequent fringe nootropic topic.

Limits, risks, and missing evidence

• Human safety/efficacy is not established.
• Stimulant-like monoaminergic effects can interact badly with MAOIs, sympathomimetics, and psychiatric vulnerability.

Risk flags

• research
• monoaminergic
• drug interactions

Linked papers, labels, and reviews

1. Regulation by TAAR1 of dopaminergic-GABAergic interaction in the striatum: effects of (-)-BPAP
   preclinical / pubmed_bpap_taar1_2025
   BPAP and TAAR1-related mechanism.
2. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
   mechanistic / pubmed_bpap_transporter_2003
   Direct BPAP transporter/source pharmacology; helps separate older monoamine-enhancer framing from newer TAAR1 hypotheses.